{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:36:03Z","timestamp":1771234563932,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ymgme.2020.06.008","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T21:11:52Z","timestamp":1592946712000},"page":"116-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy"],"prefix":"10.1016","volume":"131","author":[{"given":"Simon A.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Lidove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramod K.","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Dionisi-Vici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Veronica","family":"Munoz-Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubomyra","family":"Nalysnyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison D.","family":"Schecter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Wasserstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2020.06.008_bb0005","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13023-015-0262-5","article-title":"Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act","volume":"10","author":"Mechler","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","article-title":"Types A and B Niemann-Pick disease","volume":"120","author":"Schuchman","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13023-017-0572-x","article-title":"Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD)","volume":"12","author":"McGovern","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1212\/01.wnl.0000194208.08904.0c","article-title":"Natural history of Type A Niemann-Pick disease: possible endpoints for therapeutic trials","volume":"66","author":"McGovern","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0025","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jpeds.2006.06.034","article-title":"Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease","volume":"149","author":"Wasserstein","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0030","doi-asserted-by":"crossref","first-page":"e672","DOI":"10.1542\/peds.2004-0887","article-title":"The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study","volume":"114","author":"Wasserstein","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0035","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10545-017-0123-6","article-title":"Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months","volume":"41","author":"Wasserstein","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0040","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ymgme.2015.05.013","article-title":"Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency","volume":"116","author":"Wasserstein","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0045","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2018.11.014","article-title":"Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)","volume":"126","author":"Wasserstein","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0050","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00408-016-9893-0","article-title":"Pulmonary involvement in niemann-pick disease: a state-of-the-art review","volume":"194","author":"von Ranke","year":"2016","journal-title":"Lung"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0055","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000477465","article-title":"Interstitial lung disease associated with adult niemann-pick disease type B","volume":"94","author":"Chebib","year":"2017","journal-title":"Respiration"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0060","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1590\/s1806-37562017000000062","article-title":"Niemann-pick disease type B: HRCT assessment of pulmonary involvement","volume":"43","author":"Freitas","year":"2017","journal-title":"J. Bras. Pneumol."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0065","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ymgme.2016.05.001","article-title":"Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant): literature review and report of new cases","volume":"118","author":"Cassiman","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0070","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/gim.2013.4","article-title":"Morbidity and mortality in type B Niemann-Pick disease","volume":"15","author":"McGovern","year":"2013","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0075","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ymgme.2012.06.015","article-title":"Acid sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: disease spectrum and natural course in attenuated patients","volume":"107","author":"Hollak","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0080","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.revmed.2016.10.387","article-title":"Acid sphingomyelinase deficiency (Niemann-Pick disease type B) in adulthood: a retrospective multicentric study of 28 adult cases","volume":"38","author":"Lidove","year":"2017","journal-title":"Rev. Med. Interne"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0085","first-page":"235","article-title":"Adult-onset pulmonary involvement in Niemann-Pick disease type B","volume":"75","author":"Iaselli","year":"2011","journal-title":"Monaldi Arch. Chest Dis."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0090","series-title":"Using and Interpreting Carbon Monoxide Diffusing Capacity (Dlco) Correctly","author":"NGuyen","year":"2016"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0095","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1183\/09031936.05.00035205","article-title":"Interpretative strategies for lung function tests","volume":"26","author":"Pellegrino","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0100","author":"US Food and Drug Administration"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0105","author":"National Niemann-Pick Disease Foundation"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0110","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/ajmg.a.33077","article-title":"Psychosocial aspects of patients with Niemann-Pick disease, type B","volume":"149A","author":"Henderson","year":"2009","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0115","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1542\/peds.2007-3016","article-title":"A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B","volume":"122","author":"McGovern","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0120","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1067\/mpd.2003.113","article-title":"Growth restriction in children with type B Niemann-Pick disease","volume":"142","author":"Wasserstein","year":"2003","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0125","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10545-012-9503-0","article-title":"Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B","volume":"36","author":"Wasserstein","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0130","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/PAS.0b013e31825793ff","article-title":"Liver and skin histopathology in adults with acid sphingomyelinase deficiency (Niemann-Pick disease type B)","volume":"36","author":"Thurberg","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/gim.2015.24","article-title":"Novel first-dose adverse drug reactions during a Phase 1 trial of recombinant human acid sphingomyelinase (rhASM) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency)","volume":"18","author":"McGovern","year":"2016","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2214\/AJR.07.3550","article-title":"Correlation of MRI-Based bone marrow burden score with genotype and spleen status in Gaucher's disease AJR","volume":"191","author":"DeMayo","year":"2008","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0145","series-title":"A Collaborative Approach for Drug Development Using Gaucher Disease as a Model Guidance for Industry","author":"FDA, Pediatric Rare Diseases","year":"2017"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0150","series-title":"A Strategic Collaborative Approach from EMA and FDA, EMA\/237265\/2017","author":"EMA, Paediatric Gaucher disease","year":"2017"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","article-title":"Management goals for type 1 Gaucher disease: an expert consensus document from the European working group on Gaucher disease","volume":"68","author":"Biegstraaten","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.24572","article-title":"Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients","volume":"92","author":"Polverelli","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0170","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0175","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0180","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/03007995.2017.1415874","article-title":"Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis","volume":"34","author":"Oritani","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010298.pub2","article-title":"Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis","author":"Marti-Carvajal","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0190","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0195","first-page":"119","article-title":"Burden of illness in acid sphingomyelinase deficiency: a retrospective chart review of 100 patients","volume":"41","author":"Cox","year":"2018","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0200","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1148\/radiol.2381041696","article-title":"Type B Niemann-Pick disease: findings at chest radiography, thin-section CT, and pulmonary function testing","volume":"238","author":"Mendelson","year":"2006","journal-title":"Radiology"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0205","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0022-5223(19)35157-8","article-title":"Diffusing capacity predicts morbidity and mortality after pulmonary resection","volume":"96","author":"Ferguson","year":"1988","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0210","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/oxfordjournals.aje.a009394","article-title":"Pulmonary function levels as predictors of mortality in a national sample of US adults","volume":"147","author":"Neas","year":"1998","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0215","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccm.2019.02.005","article-title":"Incorporating lung diffusing capacity for carbon monoxide in clinical decision making in chest medicine","volume":"40","author":"Neder","year":"2019","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0220","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00096-2016","article-title":"A comparison of published multidimensional indices to predict outcome in idiopathic pulmonary fibrosis","volume":"3","author":"Sharp","year":"2017","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0225","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1177\/0300060517719767","article-title":"Clinical profile of unclassifiable interstitial lung disease: comparison with chronic fibrosing idiopathic interstitial pneumonias","volume":"46","author":"Traila","year":"2018","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0230","first-page":"344","article-title":"Patterns of interstitial lung disease and mortality in rheumatoid arthritis","volume":"56","author":"Zamora-Legoff","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0235","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.autrev.2018.02.008","article-title":"Predictors of morbidity and mortality in early systemic sclerosis: long-term follow-up data from a single-centre inception cohort","volume":"17","author":"Panopoulos","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0240","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jbmt.2017.03.018","article-title":"Systemic sclerosis: association between physical function, handgrip strength and pulmonary function","volume":"21","author":"Lopes","year":"2017","journal-title":"J. Bodyw. Mov. Ther."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0245","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2169\/internalmedicine.56.7019","article-title":"Depression is significantly associated with the health status in patients with idiopathic pulmonary fibrosis","volume":"56","author":"Matsuda","year":"2017","journal-title":"Intern. Med."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0250","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/rheumatology\/keu456","article-title":"Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis","volume":"54","author":"Wallace","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0255","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1378\/chest.09-0211","article-title":"Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis","volume":"136","author":"Swigris","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0260","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.rmed.2014.12.011","article-title":"Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: an algorithm application model","volume":"109","author":"Ruocco","year":"2015","journal-title":"Respir. Med."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0265","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000446607","article-title":"Clinical correlates of reduced physical activity in idiopathic pulmonary fibrosis","volume":"91","author":"Bahmer","year":"2016","journal-title":"Respiration"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0270","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1378\/chest.10-0608","article-title":"Depression and functional status are strongly associated with dyspnea in interstitial lung disease","volume":"139","author":"Ryerson","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.ymgme.2020.06.008_bb0275","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1007\/s10067-018-4148-5","article-title":"Vascular complications in systemic sclerosis: a prospective cohort study","volume":"37","author":"Mecoli","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0280","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.semarthrit.2011.01.002","article-title":"Determinants of work disability in patients with systemic sclerosis: a longitudinal study of the GENISOS cohort","volume":"41","author":"Sharif","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0285","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0290","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.arbres.2017.06.010","article-title":"Erratum to \"Guidelines for the medical treatment of idiopathic pulmonary fibrosis\" <[Arch. Bronconeumol. 53 (2017) 263-9] >","volume":"53","author":"Xaubet","year":"2017","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0295","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.arbres.2016.12.011","article-title":"Guidelines for the medical treatment of idiopathic pulmonary fibrosis","volume":"53","author":"Xaubet","year":"2017","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0300","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.rmr.2017.07.017","article-title":"French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2017 update. Full-length version","volume":"34","author":"Cottin","year":"2017","journal-title":"Rev. Mal. Respir."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0305","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.resinv.2019.02.003","article-title":"Evaluation and management of idiopathic pulmonary fibrosis","volume":"57","author":"Kishaba","year":"2019","journal-title":"Respir. Investig."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0310","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2020.06.008_bb0315","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ymgme.2020.02.002","article-title":"Biochemical and imaging parameters in acid sphingomyelinase deficiency: potential utility as biomarkers","volume":"130","author":"Eskes","year":"2020","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220301475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220301475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:25:13Z","timestamp":1761089113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719220301475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":63,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1096719220301475"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.06.008","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}